Zacks Research Issues Positive Estimate for AGIO Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Research analysts at Zacks Research raised their Q1 2026 earnings per share estimates for Agios Pharmaceuticals in a research report issued on Wednesday, March 4th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings of ($1.83) per share for the quarter, up from their previous estimate of ($1.85). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q2 2026 earnings at ($1.90) EPS, Q3 2026 earnings at ($1.88) EPS, Q4 2026 earnings at ($1.83) EPS, FY2026 earnings at ($7.44) EPS, Q1 2027 earnings at ($1.59) EPS, Q2 2027 earnings at ($1.63) EPS, Q3 2027 earnings at ($1.61) EPS, Q4 2027 earnings at ($1.53) EPS and FY2027 earnings at ($6.37) EPS.

Several other analysts have also recently weighed in on AGIO. HC Wainwright boosted their price objective on shares of Agios Pharmaceuticals from $62.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, February 12th. Leerink Partners lifted their target price on Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, December 26th. Truist Financial upped their price target on Agios Pharmaceuticals from $32.00 to $38.00 and gave the company a “buy” rating in a research report on Wednesday, December 24th. Citigroup increased their price target on Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $40.67.

Agios Pharmaceuticals Price Performance

AGIO opened at $28.53 on Monday. Agios Pharmaceuticals has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The company’s 50 day moving average price is $28.08 and its two-hundred day moving average price is $33.15. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -4.01 and a beta of 0.89.

Insider Buying and Selling

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,932 shares of the stock in a transaction that occurred on Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total transaction of $79,427.88. Following the transaction, the chief financial officer directly owned 37,394 shares in the company, valued at approximately $1,013,003.46. This represents a 7.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Krishnan Viswanadhan sold 2,959 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $27.80, for a total transaction of $82,260.20. Following the sale, the insider directly owned 5,141 shares of the company’s stock, valued at approximately $142,919.80. This trade represents a 36.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 36,262 shares of company stock worth $984,237 over the last three months. Insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Bellevue Group AG raised its holdings in shares of Agios Pharmaceuticals by 3.5% during the third quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock valued at $149,110,000 after purchasing an additional 124,586 shares during the period. State Street Corp grew its stake in shares of Agios Pharmaceuticals by 37.4% in the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock valued at $84,604,000 after buying an additional 845,433 shares during the period. Erste Asset Management GmbH grew its stake in shares of Agios Pharmaceuticals by 1.4% in the 4th quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock valued at $76,343,000 after buying an additional 40,000 shares during the period. Wellington Management Group LLP increased its position in Agios Pharmaceuticals by 485.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after buying an additional 2,049,287 shares in the last quarter. Finally, Commodore Capital LP increased its position in Agios Pharmaceuticals by 0.6% in the 3rd quarter. Commodore Capital LP now owns 2,338,287 shares of the biopharmaceutical company’s stock valued at $93,859,000 after buying an additional 13,287 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.